Intermediate-Dose Tinzaparin Versus Low-Dose Enoxaparin as Thromboprophylaxis in Hospitalized Internal Medicine Patients
Medical Sciences · 24.07.2026 · 14 (4) · 425
DOI: 10.3390/medsci14040425 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Medical Sciences, online erschienen am 24.07.2026. Verfasst von Aimilios Kaklamanos und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece. Hauptthemen laut MEDLINE: Enoxaparin, Heparin, Low-Molecular-Weight, Fibrinolytic Agents, Thrombosis. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background/Objectives: Acutely ill patients in hospital are at high risk for thrombosis, even post-discharge. However, the safest and most effective strategy for thromboprophylaxis in such patients is still under debate. Our aim was to compare the subcutaneous use of low-dose prophylactic enoxaparin versus intermediate-dose tinzaparin.
Methods
Patients in an internal medicine clinic of a tertiary hospital in Athens, Greece, with increased risk for thrombosis (PADUA score ≥ 4) received either intermediate-dose tinzaparin (8000 anti-Xa units) or 40 mg enoxaparin as thromboprophylaxis. Efficacy and adverse effects were evaluated and compared up to 14 days post-discharge.
Results
A total of 251 patients who received tinzaparin were compared with 95 patients under enoxaparin thromboprophylaxis. No statistically significant difference was found in the number of bleeding and/or clinically evident thrombotic events between the two groups [6 versus 14 bleeding (p = 0.2603) events and 0 versus 1 venous thrombotic event (p = 0.999) in the enoxaparin and tinzaparin groups, respectively]. Moreover, no difference was found in length of stay [enoxaparin: 10 days (95%CI: 9–12 days); tinzaparin: 8 days (95%CI: 8–10 days, HR = 1.18, 95%CI: 0.91–1.54, p = 0.2] or mortality [11 deaths with enoxaparin (11.58%, 95%CI: 6.59–19.55%) and 50 deaths with tinzaparin (19.92%, 95%CI: 15.45–25.30%, OR: 1.9, 95%CI: 0.94–3.83, p = 0.069)]. The use of thromboprophylaxis for two weeks post-discharge did not result in any bleeding or clinically evident thrombotic events in either group.
Conclusions
In our cohort, the use of intermediate-dose tinzaparin was similar to the use of low-dose enoxaparin for patients with a high PADUA score in terms of thrombotic and/or bleeding events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
- 2nd Department of Pathology, University Hospital "Attikon", National and Kapodistrian University of Athens, 12461 Athens, Greece.
ORCID-Profile: Vasileios Serepisios, Sofia Chelioti, Abraham Pouliakis, Daphnie Germanou, Dimitrios Dorotheos Papadakis, Theodoros Androutsakos
Zitieren
APA
Kaklamanos, A., Serepisios, V., Chelioti, S., Zervakou, K., Christodoulou, G., Pouliakis, A., Mikelopoulou, K., Germanou, D., Tsinokou, I., Papadakis, D. D., Tsironis, C., & Androutsakos, T. (2026). Intermediate-Dose Tinzaparin Versus Low-Dose Enoxaparin as Thromboprophylaxis in Hospitalized Internal Medicine Patients. Medical Sciences, 14(4), 425. https://doi.org/10.3390/medsci14040425
Vancouver
Kaklamanos A, Serepisios V, Chelioti S, Zervakou K, Christodoulou G, Pouliakis A, et al. Intermediate-Dose Tinzaparin Versus Low-Dose Enoxaparin as Thromboprophylaxis in Hospitalized Internal Medicine Patients. Medical Sciences. 2026;14(4):425. doi:10.3390/medsci14040425
BibTeX
@article{Kaklamanos2026,
author = {Kaklamanos, Aimilios and Serepisios, Vasileios and Chelioti, Sofia and Zervakou, Kalliopi and Christodoulou, George and Pouliakis, Abraham and Mikelopoulou, Konstantina and Germanou, Daphnie and Tsinokou, Ilias and Papadakis, Dimitrios Dorotheos and Tsironis, Christos and Androutsakos, Theodoros},
title = {Intermediate-Dose Tinzaparin Versus Low-Dose Enoxaparin as Thromboprophylaxis in Hospitalized Internal Medicine Patients},
journal = {Medical Sciences},
year = {2026},
volume = {14},
number = {4},
pages = {425},
doi = {10.3390/medsci14040425}
}
EUVIMED